Feb 12 (Reuters) - CSL Ltd (CSL) :
- TOP-LINE RESULTS FROM PHASE 3 AEGIS-II TRIAL EVALUATING EFFICACY AND SAFETY OF CSL112
- THERE WERE NO MAJOR SAFETY OR TOLERABILITY CONCERNS WITH CSL112
- STUDY DID NOT MEET ITS PRIMARY EFFICACY ENDPOINT OF MACE REDUCTION AT 90 DAYS
News: CSL CSL Says Top-Line Results From Phase 3 Aegis-II Trial Evaluating Efficacy And Safety Of...
Add to My Watchlist
What is My Watchlist?
 (20min delay)
|
|||||
|
Last
$248.39 |
Change
0.940(0.38%) |
Mkt cap ! $120.2B | |||
| Open | High | Low | Value | Volume |
| $247.65 | $249.87 | $245.75 | $183.3M | 738.0K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 100 | $248.01 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $248.39 | 251 | 1 |
View Market Depth
| Last trade - 16.12pm 17/07/2025 (20 minute delay) ? |
| CSL (ASX) Chart |